Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 114 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Quetiapine on Marijuana Withdrawal and Relapse

NCT00743366
Conditions
Marijuana Smoking
Interventions
Marijuana, Quetiapine, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Completed Phase 2Phase 3 Interventional Results available

Nabilone for Cannabis Dependence: A Pilot Study

NCT01347762
Conditions
Cannabis Dependence, Marijuana Dependence
Interventions
Nabilone, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Cannabis Use Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Inhaled Cannabis on Driving Performance

NCT01620177
Conditions
Alcohol Drinking, Cannabis
Interventions
Alcohol(oral) and placebo, Cannabis(THC)(Inhaled) and Placebo
Drug
Lead sponsor
Gary R Gaffney
Other
Eligibility
21 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Hepatitis C
Interventions
Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Smoked THC and CBD in Men and Women

NCT05037487
Conditions
Drug Abuse, Intoxication by Drug, Impairment
Interventions
Placebo Cannabis, 20 mg CBD Cannabis, 20 mg CBD + 20 mg THC Cannabis, 20 mg THC Cannabis
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alcohol Drinking, Alcohol Use, Unspecified, Alcohol Abstinence, Alcohol-Related Disorders
Interventions
Endourage 1200 mg OMD ™ Oral Mucosal Drops, Isolate, Placebo, Peppermint Oil, masking flavor
Dietary Supplement · Other
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Novato, California
Conditions
Cannabis Use Disorder
Interventions
PF 04457845, Placebo Oral Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
New Haven, Connecticut • Baltimore, Maryland • New York, New York + 1 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

CBD Cannabis Extract: Pharmacokinetic Studies

NCT04280289
Conditions
Epilepsy
Interventions
cannabidiol extract
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
University, Mississippi
Conditions
Smoking, Marijuana
Interventions
CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lexington, Kentucky • New York, New York • Charleston, South Carolina
Conditions
Antibiotics, Pituitary Adenoma
Interventions
Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 84 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Marijuana Abuse
Interventions
THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer
Interventions
Dexamethasone, Dronabinol, Mirtazapine, Nutrition Intervention
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Cannabis Use Disorder
Interventions
Broad Spectrum Cannabidiol (bsCBD) 400 mg, Broad Spectrum Cannabidiol (bsCBD) 200 mg, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Not yet recruiting Phase 1 Interventional

Cannabis and Opioid Use Disorder, Study 2

NCT07661446
Conditions
Opioid Use Disorders, Cannabis Use
Interventions
Inhaled Cannabis, Intranasal Opioid
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Back Pain, Depressive Symptoms
Interventions
CBD, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acne, Eczema, Skin Aging
Interventions
Hemptress Oil
Other
Lead sponsor
Hemptress
Industry
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Conditions
HIV Infections
Interventions
dronabinol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Gabapentin for Bipolar & Cannabis Use Disorders

NCT03334721
Conditions
Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
Interventions
Gabapentin, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Cannabis, Drug Effects, Driving Performance
Interventions
5 mg Dronabinol (Marinol®) + Placebo Beverage, 10 mg Dronabinol (Marinol®) + Placebo Beverage, 5 mg Dronabinol (Marinol®) + Alcohol Beverage, 10 mg Dronabinol (Marinol®) + Alcohol Beverage, Placebo Capsule + Alcohol Beverage, Placebo Capsule + Placebo Beverage
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
21 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
West Bend, Wisconsin
Conditions
Pain Threshold, Mood
Interventions
Placebo capsules, Inactive marijuana (0% THC), Low dose Dronabinol, High dose Dronabinol, Low THC marijuana, High THC marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Marijuana Abuse
Interventions
AEF0117, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Garden Grove, California • Los Angeles, California + 8 more
Conditions
Pain
Interventions
Medical Marijuana
Drug
Lead sponsor
The Connecticut Hospice Inc.
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Branford, Connecticut